在资产负债表方面，截至2025年9月30日，公司流动资产为6.56亿元，非流动资产为7.21亿元，流动负债 为2.66亿元，非流动负债为3.85亿元，净资产总额为7.26亿元，较2024年12月31日的7.3亿元略有下降。 此次财务数据为未经过审计，可能会在进一步内部审阅后进行调整。 (编辑：杨燕 林辰) 近日，东曜药业发布公告称，截至2025年9月30日止九个月，公司营业收入为6.22亿元，较去年同期下 降23%，主要原因是自研产品的市场竞争愈加激烈。净利润方面，公司在此期间出现亏损，净亏损为 337万元，而去年同期则实现净利润3540万元。 （东曜药业公告） ...

Group 1 - The OCS market is experiencing a four-year CAGR of 41%, indicating significant growth potential and attracting both domestic and international investment interest [1] - Three key investment directions in the OCS market are highlighted as worthy of focus for investors [1] Group 2 - Despite short-term performance pressures, an AI multimodal company has received a "buy" rating from analysts, who are optimistic about its prospects [1] - The company possesses over 100,000 hours of core video data assets, showcasing its unique value proposition [1] - The dual value of having both a scarce dataset and self-developed products is emphasized as a significant competitive advantage [1]